An Open-Label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.

Istvan Takacs Emese Mezősi Alfonso Soto Peter Kamenickỷ Marie-Lucile Figueres Maria Angeles Galvez Moreno Sandrine Lemoine Françoise Borson-Chazot Ismael Capel Taha Ouldrouis Nadège Lucas Soraya Allas Mark Sumeray Michel Ovize Michael Mannstadt

Published in: The Journal of clinical endocrinology and metabolism (2024)

Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range, while normalizing uCa excretion and producing a balanced resumption of bone turnover.

Keyphrases

bone mineral density
postmenopausal women
open label
body composition
bone loss
randomized controlled trial
double blind
clinical trial
bone marrow
placebo controlled
study protocol